drugset / Trial / NCT00148616

Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia

NCT00148616

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of 24 weeks memantine add-on treatment to risperidone for the treatment of negative symptomatology and cognitive impairment in patients with chronic schizophrenia.

Timeline

Start
2004-04
Primary completion
2008-06
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Memantine Unknown 20 mg

Indications